Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Drug Delivery
Filter     Order     Display # 
Date Item Title Hits
24 Nov 2008 Penwest Enters Into Second Research and Development Agreement With Otsuka Pharmaceutical 8744
23 Nov 2008 Covidien and Depomed Announce License Agreement 1213
13 Oct 2008 Study Finds Improved Absorption of Oral Salmon Calcitonin Versus Nasal Administration 978
19 Aug 2008 DelSite Files IND for Nasal Powder H5N1 (Bird Flu) Influenza Vaccine 746
13 Aug 2008 Tekmira Pharmaceuticals Announces RNAi Research Collaboration with Bristol-Myers Squibb 778
05 Aug 2008 Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule 841
04 Aug 2008 Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis... 742
02 Aug 2008 MDRNA, Inc. Demonstrates In Vivo Efficacy with Proprietary DiLA2 Delivery Platform 852
27 Jul 2008 Eligen(R) B12 oral formulation demonstrates 240% improvement in bioavailability versus standard oral Vitamin B12 tablet and different absorption characteristics 983
15 Jul 2008 BioAlliance Pharma suspends the Phase II/III trial of doxorubicin Transdrug(R) in primary liver cancer, following advice from the Drug Safety Monitoring Board and the Steering Committee 815
09 Jul 2008 Altus Pharmaceuticals Secures Long-Term Growth Hormone Supply For ALTU-238 Clinical Development and Commercialization 879
09 Jul 2008 Modigene Platform Validated in Independent Phase III Trial of CTP Technology 820
07 Jul 2008 Emisphere Announces Data From Independent Clinical Study of Effects of Oral GLP-1 on Glucose and Insulin Concentrations 732
29 Jun 2008 Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH) 831
24 Jun 2008 Promising Results for Oral CP-4126 916
24 Jun 2008 SurModics Announces Initiation by Merck & Co., Inc. of Phase IIb Clinical Trial for I-vation(TM) TA 839
11 Jun 2008 Lilly and TransPharma Medical Announce Licensing and Development Agreement 859
30 Apr 2008 Sepracor and Arrow Sign Global License and Development Agreement Covering Technology to Enhance Ciclesonide and BROVANA(R) Franchises 942
29 Apr 2008 Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients 918
29 Apr 2008 Phosphagenics Reports Positive Pre-clinical Results for 901
28 Apr 2008 Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon) 915
15 Apr 2008 Proof of Concept Study in Second Species Demonstrates Increase in Absorption of Oral B12 Using Emisphere Technology 1073
08 Apr 2008 Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients 896
08 Apr 2008 Pfizer Statement on Exubera Labeling Update in the United States 939
01 Apr 2008 Pantec Biosolutions unveils preclinical data for novel transdermal drug delivery platform 1128
29 Mar 2008 QLT initiates Phase II study of punctal plug drug delivery system for Glaucoma & Ocular Hypertension 847
29 Mar 2008 QLT initiates Phase II study of punctal plug drug delivery system for Glaucoma & Ocular Hypertension 934
18 Mar 2008 Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes 903
18 Mar 2008 Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses 963
13 Mar 2008 AstraZeneca signs drug delivery collaboration 1045
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 414

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Biologic and Immune Therapy of S. aureus Infections

Order Now

Recommended Report

RNA Therapeutics
Order Now

Subscribe La Merie Biologics